Choose an Affordable Anti-Herpes Product; polyDNA Recommends Gene-Eden-VIR
| PR Web |
polyDNA recommends Gene-Eden-VIR as the most affordable means of treating a latent herpes infection. As the winter holidays pass, and people break the bank on presents, polyDNA is doing its part to make it easy for individuals to afford a natural remedy against the latent herpes virus.
This week, the media, government agencies, not-for-profits, schools, financial institutions and businesses of all kinds are putting up “After Christmas Sales” or are reminding people why their products or services are better than someone else’s. To help customers who suffer from herpes infections, polyDNA compared the cost of Valtrex, Acyclovir (Zovirax), and Gene-Eden-VIR. The first two are
“I spent so much money on my kids this Christmas! Somehow, the threat of a herpes outbreak kind of got pushed to the back of my mind. I know for sure I won’t have the money to afford Valtrex over the next few months, and that’s especially true since I lost my insurance too. Things just seem to get harder and harder!” – Tamicka R.
According to goodrx.com, the cost of a month’s supply of Valtrex (90 pills), one of the most common anti-herpes medications, is
While Zovirax (Acyclovir) is significantly cheaper, this herpes medication still costs at least
Gene-Eden-VIR is the only natural antiviral product that was tested according to
“We recommend that individuals make New Year’s resolutions that improve their bank account. Choosing Gene-Eden-VIR, an affordable, clinically proven herpes remedy, is a great way to live up to that sort of resolution.” –
In a post marketing clinical study published on
Each ingredient of Gene-Eden-VIR was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the safest, most effective natural ingredients that target the latent form of herpes. (3)
To learn more about Gene-Eden-VIR, visit http://www.gene-eden-kill-virus.com. All orders of Gene-Eden-VIR are completely confidential, and no information is shared or sold to any third party. Privacy is assured.
Reference:
(1) Goodrx.com - Prices for 90 tablets of Valtrex 1g (brand).
http://www.goodrx.com/valacyclovir#/?filter-location=&coords=&label=Valtrex&form=tablet&strength=1g&quantity=custom&qty-custom=90
(2) Goodrx.com - Prices for 200 ml of 200mg/5ml Zovirax oral suspension (brand).
http://www.goodrx.com/acyclovir#/?filter-location=&coords=&label=Zovirax&form=oral+suspension&strength=200mg&quantity=custom&qty-custom=30
(3) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing
Clinical Study. Published on
http://gene-eden-kill-virus.com/PP_Gene-Eden-VIR-is-Antiviral.pdf
polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr.
In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.
polyDNA developed Gene-Eden-VIR , an antiviral natural remedy that helps the immune system kill latent viruses.
Read the full story at http://www.prweb.com/releases/2013/12/prweb11449868.htm
| Copyright: | (c) 2013 PRWEB.COM Newswire |
| Wordcount: | 598 |



Advisor News
- Proposed legislation takes aim at Social Security shortfall
- The overlooked retirement security risk that must be addressed
- What advisors should know about hedge funds in retirement planning
- Retirement control is top success measure for middle class, ACLI says
- Industry groups applaud House passage of Financial Exploitation Prevention Act
More Advisor NewsAnnuity News
- Built-in guaranteed annuities: What advisors should know
- Malibu Life Holdings Completes Acquisition of TruSpire, Establishing Malibu USA and Accelerating Entry into the U.S. Retail Annuity Market
- Why job boards are failing insurance agencies
- MassMutual Ranks No. 100 on the 2026 Fortune 500® List
- What’s fueling record annuity growth?
More Annuity NewsHealth/Employee Benefits News
- Coalition sues to protect Medicaid coverage
- Findings from George Washington University Update Understanding of Managed Care (Eligibility Assistance Increases Insurance Enrollment Within Community Health Centers but Not At the State Level): Managed Care
- Findings from Razanne Oueini and Colleagues Provides New Insights into Proinsulin (Changes in persistence to basal insulin following the Medicare out-of-pocket cost cap): Peptide Proteins – Proinsulin
- Researchers from Columbia University Detail New Studies and Findings in the Area of Managed Care (The Impact of Health Shocks On Housing Instability: Evidence From Urban Medicaid Enrollees): Managed Care
- Studies Conducted at Stanford University on Economics Recently Reported (Why Doesn’t the United States Have National Health Insurance? the Political Role of the American Medical Association): Economics
More Health/Employee Benefits NewsLife Insurance News
- Fortitude Re Announces $3.8 Billion Long-Term Care Reinsurance Agreement with Unum Group
- Unum Group Announces $3.8 Billion Long-Term Care Reinsurance Transaction with Fortitude Re
- Before you debate premium financing, understand the bigger picture
- NAIFA praises House committee approval of Clarity for Compensation Act
- PHL Variable liquidation pushed out to 2027, Connecticut regulators say
More Life Insurance News